Source 1primary paper2025MED
Toolkit/AAV-based viral vectors
AAV-based viral vectors
Also known as: AAVs, AAV viral vectors, viral vectors such as those based on AAVs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
AAV-based viral vectors are adeno-associated virus delivery systems used to introduce optogenetic transgenes for expression in target cell types. In the cited therapeutic optogenetics context, they are presented as promising for human trials but still limited by barriers to general use.
Usefulness & Problems
Why this is useful
These vectors are useful because therapeutic optogenetic efficiency depends on successful delivery and expression in the appropriate cell type. They therefore serve as a practical delivery harness for placing optogenetic payloads into target cells in translational settings.
Problem solved
AAV-based viral vectors address the delivery problem in optogenetics: getting the genetic payload into the relevant cells and achieving transgene expression there. The cited literature also links this need to applications such as closed-loop all-optical neuromodulation, where large gene cassette requirements create an added delivery challenge.
Problem links
Need precise spatiotemporal control with light input
DerivedAAV-based viral vectors are delivery systems used to express optogenetic payloads in target cells. In the cited context, they are presented as promising for human trials but still limited by barriers to general use.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
transgene expression in target cell typestransgene expression in target cell typestransgene expression in target cell typesTranslation Controlviral gene deliveryviral gene deliveryviral gene deliveryTechniques
Functional AssayTarget processes
translationInput: Light
Implementation Constraints
application area: cardiac gene therapyapplication area: retinal gene deliverycofactor dependency: cofactor requirement unknowncofactor dependency: requires exogenous cofactordelivery routes named: intravitreal or subretinaldelivery routes named: intravitreal or subretinalencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenimplementation constraint: spectral hardware requirementoperating role: deliverysystem: mammalian cells
The available evidence supports only that therapeutic efficiency depends on vector delivery and expression in the appropriate cell type. No construct architecture, serotype choice, promoter strategy, packaging limit, dosing, or manufacturing details are provided in the supplied material.
The cited source explicitly states that barriers to general use remain for AAV-based viral vectors. It also notes that large gene cassette requirements are a challenge in combined optogenetic actuator-indicator systems, but the specific nature of the AAV-related barriers is not detailed in the supplied evidence.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2review2020Frontiers in Neural Circuits
Source 3review2025Biomolecules
Ranked Claims
Clinical translation of optogenetic therapy for AMD faces challenges and requires further development.
AAVs serve as delivery vectors in retinal disease models via intravitreal or subretinal injections.
In retinal disease models, adeno-associated viruses (AAVs) serve as delivery vectors via intravitreal or subretinal injections.
In retinal disease models, AAVs serve as delivery vectors for optogenetic approaches via intravitreal or subretinal injection.
AAV viral vectors have become one of the most important viral vectors for gene transfer, especially in mammalian cells.
Adeno-associated virus (AAVs), initially identified as contaminants of adeno-virus preparations, have since become one of the most important viral vectors for gene-transfer, especially in mammalian cells.
The paper discusses optogenetic tools, delivery methods, challenges, future directions, preclinical AMD models, and clinical translation potential for AMD-related vision loss.
This review explores the principles of optogenetics, its application in preclinical AMD models, and the potential for clinical translation of this approach. We discuss the various optogenetic tools, delivery methods, and the challenges and future directions in harnessing this technology to combat AMD-related vision loss.
The source analyzes and summarizes various AAV serotypes used in gene therapy programs for preclinical and clinical cardiac disease studies.
This review analyzes and summarizes various AAV serotypes utilized in gene therapy programs for preclinical and clinical assays for cardiac disease.
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Combining optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation, but introduces challenges including spectral orthogonality, decision-making computational algorithms, and large gene cassette requirements.
the combined use of optogenetic actuators and indicators could enable closed-loop all-optical neuromodulation. Such systems would introduce additional challenges related to spectral orthogonality between actuator and indicator, the need for decision making computational algorithms and requirements for large gene cassettes
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Approval Evidence
2 sources5 linked approval claimsfirst-pass slugs aav-based-viral-vectors, adeno-associated-virus-aav-viral-vectors
Adeno-associated virus (AAVs), initially identified as contaminants of adeno-virus preparations, have since become one of the most important viral vectors for gene-transfer, especially in mammalian cells.
Source:
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain
Source:
importance statementsupports
AAV viral vectors have become one of the most important viral vectors for gene transfer, especially in mammalian cells.
Adeno-associated virus (AAVs), initially identified as contaminants of adeno-virus preparations, have since become one of the most important viral vectors for gene-transfer, especially in mammalian cells.
Source:
scope statementsupports
The source analyzes and summarizes various AAV serotypes used in gene therapy programs for preclinical and clinical cardiac disease studies.
This review analyzes and summarizes various AAV serotypes utilized in gene therapy programs for preclinical and clinical assays for cardiac disease.
Source:
delivery requirementsupports
Therapeutic efficiency of optogenetics depends on vector delivery and expression in the appropriate cell type.
As in any gene therapy, the therapeutic efficiency of optogenetics will rely on vector delivery and expression in the appropriate cell type.
Source:
limitationmixed
AAV-based viral vectors show potential in human trials, but their broader use is limited by immune responses, delivery and transport barriers, and liver clearance.
Although viral vectors such as those based on AAVs are showing great potential in human trials, barriers to their general use remain, including immune responses, delivery/transport, and liver clearance.
Source:
limitationsupports
Current approved vectors have gene cassette size limitations that need to be addressed for therapeutic optogenetics.
Limitations associated with the gene cassette size which can be packaged in currently approved vectors also need to be addressed.
Source:
Comparisons
Source-backed strengths
The supplied evidence states that viral vectors based on AAVs are showing great potential in human trials. This supports their relevance for therapeutic translation, but the evidence provided does not include quantitative performance metrics, tropism data, or expression benchmarks.
Compared with adenoviral infection
AAV-based viral vectors and adenoviral infection address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: viral gene delivery; same primary input modality: light
Compared with adenovirus
AAV-based viral vectors and adenovirus address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: viral gene delivery; same primary input modality: light
Compared with Near-infrared-light activatable nanoparticles
AAV-based viral vectors and Near-infrared-light activatable nanoparticles address a similar problem space.
Shared frame: same top-level item type; same primary input modality: light
Ranked Citations